🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of a Multi-infusion Strategy in Neonatology on the Rate of Central Line-associated Bloodstream Infections

Recruitingn/aAges any - 32 WeeksAllHospices Civils de Lyon
NCT06656104 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The management of premature infants hospitalized in neonatal units requires the simultaneous intravenous (IV) infusion of several drugs and parenteral nutrition solutions, when oral administration is impossible or unsuitable. IV administration requires the use of a central venous catheter and an infusion set that connects the catheter to the infusion fluid or drug. The use of multiple infusion devices exposes patients to central line-associated bloodstream infections (CLABSI), drug interactions, abnormal administration timing and repetition of procedures in close proximity to the infant. Against this backdrop, DORAN INTERNATIONAL has developed the EDELVAISS multi-infusion strategy (Multiline Neo® and Escape Line® devices) adapted to neonatology. Given its characteristics, the benefits expected from the use of this strategy are: 1) to reduce the risk of microbial contamination and theref

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Gestational age at birth ≤ 32 weeks * Birthweight ≤ 1600 g * Admitted in the first 3 days of life in the neonatal unit * Hospitalized in the neonatal unit for at least 1 day * Survived the first three days of life * Requires the use of infusion sets for the administration of multiple drugs or solutions, whether or not they have the device in place * Receipt of the non-opposition from parents or guardians Exclusion Criteria: * Opposition by parents or guardians * Lethal or complicated malformation * Chromosomal anomaly * Participation of the infant in any other research that may interfere with the results of this study, in the judgment of the investigator
💊

What it tests

  • Reference strategy
  • Experimental strategy
📍

Where

3 sites
Service de néonatologie Hôpital Femme Mère Enfant
Bron, France
Service Pédiatrie néonatale et réanimations CHU Montpellier
Montpellier, France
Service de néonatologie CHU de Strasbourg
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy